Introduction
============

Classic Hodgkin lymphoma (cHL) is a germinal center-derived B-cell neoplasm characterized by a small number of tumor cells in a wide range of reactive infiltrating cells. cHL accounts for \~95% of HL cases ([@b1-mmr-16-04-4685]). The incidence of the HL is 2.8 per 100,000 individuals ([@b2-mmr-16-04-4685]). It was estimated that 8,500 people in the United States would be diagnosed with HL and 1,120 mortalities would be caused by HL in 2016 ([@b3-mmr-16-04-4685]). Currently, cHL treatments include cytotoxic chemotherapy and involved-field radiation therapy. These treatments significantly reduce the mortality rate and produce a 5-year overall survival rate of 70--80%; however, \~20% of patients still develop progressive disease following these treatments ([@b4-mmr-16-04-4685]). However, the pathogenesis of cHL is multifactorial and complex, therefore, improving the understanding of the molecular mechanisms involved in the pathogenesis of cHL is important for identification of novel therapeutic targets. In recent years, the pathogenic mechanisms of cHL have been extensively investigated; for example, CD30 has been demonstrated to be expressed on Hodgkin and Reed/Sternberg (HRS) cells in cHL and involved in development of cHL. The monoclonal antibody against CD30, termed Brentuximab vedotin, has been demonstrated to be a highly effective treatment for relapsed/refractory cHL ([@b5-mmr-16-04-4685]), which supports that it is important to identify more potential targets for the treatment of cHL.

Microarray analysis has become an extensively used tool for the generation of gene expression data on a genomic scale. In the current study, GSE12453 microarray data from Brune *et al* ([@b6-mmr-16-04-4685]) was downloaded. Brune *et al* ([@b6-mmr-16-04-4685]) investigated differentially expressed genes (DEGs) among cHL, B-cell non-Hodgkin lymphoma and normal B cell samples ([@b6-mmr-16-04-4685],[@b7-mmr-16-04-4685]). In the current study, DEGs were identified by comparing cHL and normal B cells samples, and gene function enrichment analysis, protein-protein interaction (PPI) network construction and co-expression sub-network construction were performed to identify the molecular markers of cHL. The results of the current study present candidate genes for future research into the pathogenic mechanisms of cHL and may help to establish novel diagnostic markers and therapeutic targets.

Materials and methods
=====================

### Microarray data

The raw data of GSE12453 based on the GPL570 platform (HG-U133_Plus_2) contributed by Brune *et al* ([@b6-mmr-16-04-4685]) were downloaded from the Gene Expression Omnibus database (<http://www.ncbi.nlm.nih.gov/geo/>). The GSE12453 dataset comprises 67 samples, including 12 cHL samples, 5 nodular lymphocyte-predominant Hodgkin lymphoma samples, 25 non-Hodgkin lymphoma samples and 25 normal B cells samples. The normal B cell samples are further divided into five subtypes: Normal naive B cells, normal memory B cells, normal centrocytes, normal centroblasts and normal plasma cells. Research has previously identified that HRS cells originate from germinal center (GC) B cells ([@b8-mmr-16-04-4685]), which contain centrocytes and centroblasts ([@b9-mmr-16-04-4685]). Under normal circumstances, GCB cells differentiate into memory B cells or plasma cells; however, GCB cells can transform into malignant B cells. Therefore, in the current study, the cHL samples and the normal B cell samples, which included GCB cells, memory B cells and plasma cells, were used for analysis.

### Data preprocessing and differential expression analysis

Several R packages was used for raw microarray data preprocessing, including concluding quality assessment (QA), quality control (QC), background correction and normalization. The R packages using for QA/QC were simpleaffy ([@b10-mmr-16-04-4685]), affyPLM and arrayQualityMetrics ([@b11-mmr-16-04-4685]). Through QC checks, the sample GSM312887 within the dataset was disqualified ([Fig. 1](#f1-mmr-16-04-4685){ref-type="fig"}) and excluded from subsequent analysis. Robust multi-array average (RMA) ([@b12-mmr-16-04-4685]) was used to perform background correction, normalization and probe summarization. The empirical Bayesian method in limma package ([@b13-mmr-16-04-4685]) was used to perform the differential analysis, \|log2 fold change (FC)\| \>2.5 and adjusted P\<0.001 were considered as statistically significant.

### Gene ontology (GO) and pathway enrichment analyses

GO is a popular approach to categorize the representation of genes and the attributes of gene expression. The Kyoto Encyclopedia of Genes and Genomes (KEGG; <http://www.genome.jp/kegg/>) ([@b14-mmr-16-04-4685]) is an online database with collected information of genomes, biological chemicals and enzymatic pathways. Database for Annotation, Visualization and Integrated Discovery (DAVID; <https://david-d.ncifcrf.gov/>), is an exploratory visualization tool that help investigators determine the biological function a series of genes. To understand the function of the DEGs, the GO and pathway enrichment analyses were performed by using DAVID 6.8 (Beta) online tool, the threshold was set as P\<0.01.

### PPI network and co-expression module construction

The Search Tool for the Retrieval of Interacting Genes (STRING 10.0) is a database that was designed to predict the PPI between DEGs ([@b15-mmr-16-04-4685]) and combination score \>0.4 was considered to be significant. Cytoscape software was used to visualize the results of the PPI network ([@b16-mmr-16-04-4685]), the sub-networks of co-expression were constructed by ClusterONE ([@b17-mmr-16-04-4685]) at the base of PPI network. ClusterONE is the plug-in component of Cytoscape designed to identify closely connected and potentially overlapping regions in the PPI network (ClusterONE parameters: Minimum size, 3; minimum density, 0; overlap threshold, 0.8). GO and KEGG pathway enrichment analysis of modular genes was implemented using the DAVID online tool.

Results
=======

### DEGs between Hodgkin lymphoma and normal B cells

A total of 450 DEGs were obtained from analysis of the dataset GSE12453, of which 214 were upregulated and 234 were downregulated genes. The distribution of DEGs is presented in [Fig. 2](#f2-mmr-16-04-4685){ref-type="fig"}.

### GO and pathway enrichment analyses

Analysis of GO and pathway enrichment for upregulated and downregulated genes was performed. The top three GO terms of functional classification are presented in [Table I](#tI-mmr-16-04-4685){ref-type="table"}. The results indicated that upregulated DEGs primarily were involved in the GO terms relevant to immune response (P=8.10×10^−29^), defense response (P=1.81×10^−19^) and cell activation (P=2.13×10^−18^). The GO terms predominantly associated with downregulated DEGs were the B cell receptor signaling pathway (P=2.61×10^−15^), B cell activation (P=1.10×10^−11^) and antigen receptor-mediated signaling pathway (P=5.08×10^−10^).

The KEGG pathways enrichment of DEGs are presented in [Table II](#tII-mmr-16-04-4685){ref-type="table"}. The upregulated DEGs were mainly enriched in transcriptional misregulation in cancer (P=6.64×10^−6^), Toll-like receptor signaling pathway (P=2.59×10^−5^), cytokine-cytokine receptor interaction (P=3.23×10^−5^), the downregulated DEGs were enriched in B cell receptor signaling pathway (P=1.90×10^−6^), Fc γ receptor-mediated phagocytosis (P=0.006327) and nuclear factor-κB signaling pathway (P=0.007157).

### PPI network and module analysis

The PPI network of DEGs was constructed ([Fig. 3](#f3-mmr-16-04-4685){ref-type="fig"}). There were 230 nodes and 694 interactions, the top 10 genes with the highest degrees in the PPI network were interleukin 6 (IL6; degree, 43), protein tyrosine phosphatase, receptor type C (PTPRC; degree, 34), signal transducer and activator of transcription 1 (STAT1; degree, 34), matrix metallopeptidase 9 (MMP9; degree, 30), spleen tyrosine kinase (SYK; degree, 27), C-C motif chemokine receptor 7 (degree, 25), fibronectin 1 (degree, 23), TIMP metallopeptidase inhibitor 1 (degree, 22), integrin subunit β1 (degree, 21) and clusterin (degree, 19; [Table III](#tIII-mmr-16-04-4685){ref-type="table"}). These genes were selected as the hub nodes. Four modules were obtained from the PPI network of DEGs ([Fig. 4](#f4-mmr-16-04-4685){ref-type="fig"}). The significant GO-biological process terms and KEGG pathway enrichment analysis for co-expression modules genes is presented in [Table IV](#tIV-mmr-16-04-4685){ref-type="table"}.

In module 1, all the DEGs were upregulated genes. STAT1 (degree, 7), C-X-C motif chemokine ligand (CXCL) 9 (degree, 5), CXCL10 (degree, 4) and IL6 (degree, 4) had high degrees. The analysis of GO function and pathway enrichment for DEGs demonstrated that all DEGs in module 1 were most enriched in the GO terms response to cytokine (P=3.21×10^−12^) and the chemokine signaling pathway (P=1.65×10^−5^). All DEGs in module 2 were downregulated genes, and the enriched GO terms were B cell activation (P=1.55×10^−6^) and B cell receptor signaling pathway (P=1.86×10^−6^). The DEGs in module 2 were most enriched in the B cell receptor signaling pathway (P=8.06×10^−11^). Furthermore, in module 2, B-cell linker protein (BLNK) and phospholipase C γ2 (PLCG2) were the two genes which were listed in the top 10 of all downregulated genes. The DEGs with the high degree in module 2, were CD79B (degree, 7), PLCG2 (degree, 5) and SYK (degree, 5).

In module 3, the most enriched KEGG pathway for the DEGs was the tumor necrosis factor signaling pathway (P=0.045025), which was associated with suppressor of cytokine signaling 3 and MMP9 genes. MMP9 was one of the most significant upregulated genes. In module 4, the most enriched GO term was leukocyte differentiation (P=3.27×10^−6^), and the enriched KEGG pathways included cell adhesion molecules and primary immunodeficiency. PTPRC had the highest degree (degree, 5) in module 4.

Discussion
==========

cHL is a type of malignancy that originates from B cells. The pathogenic mechanisms of cHL remain unclear. In the present study, the molecular mechanisms of cHL were investigated using bioinformatics with aim to provide data that could lead to the development of useful therapeutics. A total of 450 DEGs were identified by comparing expression in cHL and normal B cells, among which 216 were upregulated and 234 were downregulated. The GO-BP that was most enriched among all DEGs was immune response. The immune response has a vital role in the pathogenesis of HL, and HRS cells apply various mechanisms to escape innate immune responses by secreting various factors and inducing an immunosuppressive phenotype in T cells and monocytes ([@b18-mmr-16-04-4685]). The upregulated DEGs were predominantly enriched in the KEGG pathways, transcriptional misregulation in cancer, Toll-like receptor signaling and cytokine-cytokine receptor interaction. Downregulated DEGs were most enriched in the KEGG pathway B cell receptor signaling.

B cell receptor signaling has been previously demonstrated to be a major driver of the pathological mechanisms of B-cell malignancies ([@b19-mmr-16-04-4685]). The B cell receptor is a transmembrane protein located on the external surface of B cells and consists of heavy (IgH) and light (IgL) chains linked to a CD79A (Igα) and CD79B (Igβ) molecule ([@b20-mmr-16-04-4685]). BLNK and SYK act as crucial downstream components to transduce B cell receptor signals ([@b21-mmr-16-04-4685]). In the current study, SYK, BLNK, CD79B and PLCG2 were identified to be differentially expressed and enriched in the B cell receptor signaling pathway. SYK, BLNK and CD79B were downregulated the present study, which is in line with previously published data ([@b22-mmr-16-04-4685],[@b23-mmr-16-04-4685]); however, an association between PLCG2 and cHL not been previously reported. Another report suggested that CD79B and BLNK downregulation in HRS cells was mediated by the effect of latent membrane protein 1 (LMP1) ([@b24-mmr-16-04-4685]); however, the production of LMP1 is caused by Epstein-Barr virus infection. SYK was identified as a hub gene in PPI network in the current study, BLNK was the most significantly downregulated genes, and CD79B and PLCG2 had the highest degrees in module 2. Thus, the downregulation of SYK, BLNK, CD79B and PLCG2 potential has a crucial role in the pathogenesis of cHL, through B cell receptor signaling pathway and Epstein-Barr virus infection.

In cHL, defective transcription regulation can lead to a loss of immunoglobulin expression and B cell receptor downregulation, which facilitates evasion of apoptosis by HRS cells ([@b24-mmr-16-04-4685]--[@b26-mmr-16-04-4685]). IL6 and MMP9 were enriched in the transcriptional misregulation in cancer KEGG pathway, therefore we hypothesize that IL6 and MMP9 may have an important role in cHL pathogenesis. HRS cells can create a tumorigenic microenvironment by secreting certain cytokines and chemokines ([@b27-mmr-16-04-4685]); IL6 is considered to be an important cytokines associated with the occurrence of HL ([@b28-mmr-16-04-4685]) and may predict patient prognosis ([@b29-mmr-16-04-4685]). Furthermore, IL6 participates in the pathway of cytokine-cytokine receptor interaction. Notably, the results of the current study indicated that CD30 (also termed TNF receptor superfamily member 8) is also involved in the same pathway. As it has been previously established that expression of CD30 is characteristic in cHL ([@b30-mmr-16-04-4685]), there may be an interactive effect between IL6 and CD30. IL-6 had the highest degree of connectivity in PPI network. Taken together, this suggests that IL-6 participates in the pathogenesis of HL. The another molecule, MMP9, enriched in the transcriptional misregulation in cancer pathway and was a hub protein in the PPI network in the present study, and has also been previously reported to be associated with reduced overall survival in patients with cHL ([@b31-mmr-16-04-4685]) through effects on immune system regulation ([@b32-mmr-16-04-4685]). A previous study has suggested that the patients with aggressive non-Hodgkin lymphoma and MMP9 expression had poor overall survival ([@b33-mmr-16-04-4685]). Therefore, we hypothesize that MMP9 may be a key molecule involved in the development of classic Hodgkin lymphoma.

STAT1 has interconnectivity with IL6 and CD274/programmed death-ligand 1 (PD-L1) in the GO term of response to cytokine and immune response. It has been well documented that tumor cells expressing CD274/PD-L1 on their surface and using the programmed cell death 1 (PD-1) pathway to evade antitumor immune response, so CD274/PD-L1 has been regarded as an independent prognostic factor for cHL ([@b34-mmr-16-04-4685]--[@b36-mmr-16-04-4685]). Furthermore, it was reported that PD-1 blockade with nivolumab has been successful for cHL treatment ([@b37-mmr-16-04-4685]). module 1 in the current study suggests that STAT1 has a cross communication with CD274/PD-L1 and IL6 in pathogenesis of HL. Additionally, Butterbach *et al* ([@b38-mmr-16-04-4685]) demonstrated that STAT1 was significantly associated with lymphoma risk ([@b39-mmr-16-04-4685]), indicating that STAT1 may have a key role in pathogenesis of cHL. PTPRC is also known as CD45, which was a downregulated DEGs that represent the highest degree in module 4 in the current study. PTPRC/CD45^−^ has become a cell marker criteria for the diagnosis of cHL ([@b39-mmr-16-04-4685],[@b40-mmr-16-04-4685]), this is consistent with the findings of the current study and further confirmed the reliability the results.

In conclusion, DEGs and pathways that may be involved in pathogenesis of cHL were identified by a comprehensive bioinformatics analysis in the present study. The findings may be useful for understanding the underlying molecular mechanisms of cHL. DEGS including IL6, STAT1, MMP9, SYK, BLNK, PLCG2 and CD79B, and the pathways of B cell receptor signaling, Epstein-Barr virus infection and transcriptional misregulation in cancer may potentially to be used as diagnostic and therapeutic targets in cHL. However, the present study had limited of sample size, which may give rise to a high false-positive rate. Additionally, this study lacked experimental verification, therefore, the findings require additional genetic and experimental studies to validate the results.
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###### 

GO enrichment analysis for differentially expressed genes.

  A, Upregulated genes                                               
  ---------------------------------------------------------- ------- --------------
  GOTERM_BP_FAT                                                      
    GO:0006955 immune response                               73      8.10×10^−29^
    GO:0006952 defense response                              64      1.81×10^−19^
    GO:0001775 cell activation                               46      2.13×10^−18^
  GOTERM_CC_FAT                                                      
    GO:0005615 extracellular space                           49      1.56×10^−13^
    GO:0009897 external side of plasma membrane              19      5.93×10^−10^
    GO:0005576 extracellular region                          86      4.44×10^−9^
  GOTERM_MF_FAT                                                      
    GO:0008009 chemokine activity                            8       4.51×10^−7^
    GO:0042379 chemokine receptor binding                    8       1.74×10^−6^
    GO:0005518 collagen binding                              8       5.25×10^−6^
                                                                     
  B, Downregulated genes                                             
                                                                     
  Term                                                       Count   P-value
                                                                     
  GOTERM_BP_FAT                                                      
    GO:0050853 B cell receptor signaling pathway             14      2.61×10^−15^
    GO:0042113 B cell activation                             18      1.10×10^−11^
    GO:0050851 antigen receptor-mediated signaling pathway   16      5.08×10^−10^
  GOTERM_CC_FAT                                                      
    GO:0019814 immunoglobulin complex                        7       6.34×10^−8^
    GO:0098552 side of membrane                              16      5.16×10^−6^
    GO:0042571 immunoglobulin complex, circulating           5       3.76×10^−5^
  GOTERM_MF_FAT                                                      
    GO:0034987 immunoglobulin receptor binding               5       6.35×10^−5^
    GO:0003823 antigen binding                               7       3.36×10^−4^
    GO:0005070 SH3/SH2 adaptor activity                      5       8.38×10^−4^

GO, gene ontology; BP, biological process; CC, Cell Component; MF, molecular function.

###### 

Pathway enrichment analysis for DEGs (top three pathways with lower P-value).

  A, Upregulated DEGs                                                                     
  ----------------------- ----------------------------------------- ------- ------------- --------------------------------------------------------------------------------------------------
  hsa05202                Transcriptional misregulation in cancer   13      6.64×10^−6^   IL6, MMP9, GZMB, CD14, CCR7, CCND2, CDKN1A, ID2, IL1R2, ILRB, PLAU, MAF, CEBPB
  hsa04620                Toll-like receptor signaling pathway      10      2.59×10^−5^   IL6, STAT1, CCL3L3, CCL5, CXCL10, CXCL9, CD14, TLR8, CTSK, NFKBIA
  hsa04060                Cytokine-cytokine receptor interaction    14      3.23×10^−5^   IL6, TNFRSF8, CCL3L3, IL2RB, CXCL10, CXCL13, TNFSF13B CXCL9, HGF, IL7R, IL2RA, CCR7, ILR2, CCL5,
                                                                                          
  B, Downregulated DEGs                                                                   
                                                                                          
  KEGG-ID                 Pathway                                   Count   P-value       Genes
                                                                                          
  hsa04662                B cell receptor signaling pathway         8       1.90×10^−6^   BLNK, PLCG2, PIK3CG, SYK, CD22, CR2 CD79B, RASGRP3
  hsa04666                Fc γ receptor-mediated phagocytosis       5       0.006327      PLCG2, SYK, PTPRC, PIK3CG, PRKCB
  hsa04064                Nuclear factor-κB signaling pathway       5       0.007157      BLNK, PLCG2, SYK, ATM, TRAF5

KEGG, Kyoto encyclopedia of genes and genomes.

###### 

Top 30 genes with high node degrees in protein-protein interaction network.

  Node     Degree   Log~2~FC   P-value
  -------- -------- ---------- --------------
  IL6      43       6.104794   1.70×10^−16^
  PTPRC    34       −2.90851   5.81×10^−8^
  STAT1    34       3.312368   2.32×10^−11^
  MMP9     30       6.104794   1.70×10^−16^
  SYK      27       −3.26862   1.42×10^−13^
  CCR7     25       3.468633   4.71×10^−9^
  FN1      23       2.724853   4.07×10^−5^
  TIMP1    22       3.760919   1.10×10^−13^
  ITGB1    21       −2.51558   1.79×10^−7^
  CLU      19       3.648265   6.08×10^−10^
  FOXO1    19       −2.75234   3.69×10^−11^
  CD2      17       3.81545    3.05×10^−11^
  CD44     17       2.723706   1.01×10^−5^
  CDKN1A   17       2.675301   5.78×10^−11^
  IL2RB    17       2.508374   7.95×10^−9^
  IL7R     17       2.992393   2.53×10^−8^
  C3       16       2.959825   3.96×10^−11^
  CTLA4    16       2.526753   6.14×10^−8^
  GZMB     16       3.199213   1.98×10^−6^
  ATF3     15       3.309377   6.60×10^−9^
  CTSB     15       4.85476    1.31×10^−13^
  CXCL10   15       4.932454   2.34×10^−9^
  CXCL13   15       3.913023   3.35×10^−9^
  JAK1     15       −2.71728   3.14×10^−10^
  PIK3CG   15       −3.42779   1.20×10^−8^
  PLCG2    14       −3.00981   6.24×10^−15^
  PRKCB    14       −3.14768   1.48×10^−7^
  CCL5     13       5.047877   9.47×10^−14^
  CD79B    13       −3.73922   1.95×10^−13^
  CXCL9    13       5.293566   1.59×10^−9^

Negative log~2~FC values correspond to downregulated genes and positive log~2~FC values correspond to upregulated genes. FC, fold change.

###### 

Significant GO-BP terms and KEGG pathway enrichment analysis of genes in co-expression modules.

  A, module 1                                                                                               
  ------------- -------------------------------------------------------------------- ------- -------------- ----------------------------------------------------------------------
  GO:0034097    Response to cytokine                                                 10      3.21×10^−12^   IL6, STAT1, TNFAIP3, CCL18, NFKBIA, GBP2, CXCL9, GBP1, CXCL10, CD274
  GO:0071345    Cellular response to cytokine stimulus                                 9     1.88×10^−10^   IL6, STAT1, CCL18, NFKBIA, GBP1, GBP2, CXCL9, CXCL10, TNFAIP3
  GO:0006955    Immune response                                                      10      1.43×10^−9^    IL6, STAT1, TNFAIP, CCL18, NFKBIA, GBP2, CXCL9, GBP1, CXCL10, CD274
  hsa04062      Chemokine signaling pathway                                            5     1.65×10^−5^    STAT1, CXCL9, CXCL10, GBP2, CCL18
  hsa04668      TNF signaling pathway                                                  4     1.15×10^−4^    IL6, CXCL10, TNFAIP3, GBP2
                                                                                                            
  B, module 2                                                                                               
                                                                                                            
  ID            Description                                                          Count   P-value        Genes
                                                                                                            
  GO:0042113    B cell activation                                                      5     1.55×10^−6^    SYK, BLNK, PLCG2, BANK1, CR2
  GO:0050853    B cell receptor signaling pathway                                      4     1.86×10^−6^    SYK, CD79B, PLCG2, BLK
  GO:0002429    Immune response-activating cell surface receptor signaling pathway     5     6.63×10^−6^    SYK, BLK, PLCG2, CD79B, CR2
  hsa04662      B cell receptor signaling pathway                                      6     8.06×10^−11^   SYK, BLNK, PLCG2, CD22, CD79B, CR2
  hsa05169      Epstein-Barr virus infection                                           3     0.007086       SYK, PLCG2, CR2
                                                                                                            
  C, module 3                                                                                               
                                                                                                            
  ID            Description                                                          Count   P-value        Genes
                                                                                                            
  GO:0031667    Response to nutrient levels                                            4     3.93×10^−4^    SOCS3, ATF3, COL1A1, SPARC
  hsa04668      TNF signaling pathway                                                  2     0.045025       SOCS3, MMP9
                                                                                                            
  D, module 4                                                                                               
                                                                                                            
  ID            Description                                                          Count   P-value        Genes
                                                                                                            
  GO:0002521    Leukocyte differentiation                                              5     3.27×10^−6^    PTPRC, ITGB1, CD2, CD3D, TYROBP
  GO:0030097    Hemopoiesis                                                            5     2.00×10^−5^    PTPRC, ITGB1, CD2, CD3D, TYROBP
  hsa04514      Cell adhesion molecules                                                3     0.004048       PTPRC, ITGB1, CD2,

GO-BP, gene ontology-biological process; KEGG, Kyoto encyclopedia of genes and genomes.
